Deutsche Bank analysts Alethia Young and Robyn Karnauskas raised their price target for shares of Intercept (ICPT) to $400 from $300 citing an improved competitive position after Genfit (GNFT) announced that its trial in NASH patients did not hit on the pre-specified endpoint. The analysts think Intercept's potential treatment for NASH, known as OCA, has been strengthened relative to Genfit's GFT-505. They also see less risk to Intercept shares given reduced competitive and regulatory risk. The analysts reiterate a Buy rating on Intercept. The stock closed yesterday up $22.05 to $282.69.